Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Table 2 Immunophenotyping in case 1

Parameter	Pre-COVID-19	Pre-RGN	Post-RGN	Normal
IgA (g/L)	0.69	0.74	0.44	0.64–2.97
IgG (g/L)	4.6	3.7	3.1	5.8–15.4
IgM (g/L)	0.05	0.06	0.07	0.24–1.90
CD3 + (cells/µL)	1030	1017	N/D	690–2540
CD19 + (cells/µL)	0	360	N/D	90–660
CD16 + /CD56 + (cells/µL)	163	168	N/D	90–590
CD3 + /CD4 + (cells/µL)	N/D	345	N/D	410–1590
CD3 + /CD8 + (cells/µL)	N/D	677	N/D	190–1140
Lymphocytes (cells/µL)	1204	1552	N/D	N/A

The absence of B cells (CD19 +) prior to COVID-19 reflects treatment with glofitamab and prior therapy with rituximab. Although B cell numbers recovered following discontinuation of glofitamab, hypogammaglobulinaemia persisted
N/D not done, N/A not applicable

ISSN: 1476-0711